Adial Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Findings underscore the liver safety of ad04 as compared to placebo in the prior phase 3 clinical trial findings underscore the liver safety of ad04 as compared to placebo in the prior phase 3 clinical trial

Received favorable feedback from us and eu regulatory agencies advancing discussions with potential strategic partners received $4.3 million in gross proceeds from warrant exercises subsequent to year-end 2023 glen allen, va., april 02, 2024 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw) (“adial” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2023 fiscal year ended december 31, 2023.

Charlottesville, va., march 01, 2024 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil) (“adial” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,150,000 shares of common stock of the company originally issued in october 2023, having an exercise price of $2.82 per share and eighteen months term. the shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on form s-1 (no...

New patent strengthens adial's patent portfolio and covers ad04's unique ability to target the serotonin transporter gene for the potential treatment of opioid use disorder new patent strengthens adial's patent portfolio and covers ad04's unique ability to target the serotonin transporter gene for the potential treatment of opioid use disorder

Charlottesville, va / accesswire / february 15, 2024 / adial pharmaceuticals, inc. (nasdaq:adil)(nasdaq:adilw) ("adial" or the "company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the winter wrap-up microcap rodeo conference, which will be held virtually tuesday, february 20 through friday, february 23, 2024. cary claiborne, chief executive officer of adial, is scheduled to present on tuesday, february 20 at 11:30 a.m.

Adial Pharmaceuticals Inc (NASDAQ: ADIL) is up 60% today following a promising update on its alcohol disorder drug. What it means for Adial Pharmaceuticals stock The $7.7 million company based out of Virginia, United States said its AD04 did well in a clinical trial of Alcohol Use Disorder (AUD) patients.

Adial Pharmaceuticals (NASDAQ: ADIL ) stock is heading higher on Wednesday following positive results from a peer review of its Alcohol Use Disorder ( AUD ) treatment. This peer review focuses on Phase 3 clinical trial results for AD04.

CHARLOTTESVILLE, VA / ACCESSWIRE / February 15, 2024 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Winter Wrap-Up MicroCap Rodeo Conference, which will be held virtually Tuesday, February 20 through Friday, February 23, 2024. Cary Claiborne, Chief Executive Officer of Adial, is scheduled to present on Tuesday, February 20 at 11:30 a.m.

Adial Pharmaceuticals, Inc. (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CHARLOTTESVILLE, VA / ACCESSWIRE / October 19, 2023 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Fall Foliage MicroCap Rodeo Conference that will be held virtually Tuesday, October 24th through Friday, October 27th, 2023. Cary Claiborne, CEO of Adial Pharmaceuticals, is scheduled to present on Wednesday, October 25th, at 10:30 a.m.

CHARLOTTESVILLE, Va., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial Pharmaceuticals, will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.

CHARLOTTESVILLE, Va., June 01, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced today that it will be presenting at the Jefferies 2023 Global Healthcare Conference being held June 7-9, 2023, at the Marriott Marquis in New York, NY.

Here is how Adial Pharmaceuticals, Inc. (ADIL) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.

Penny stocks under $1 to watch right now. The post 10 Hot Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Bet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enterprises (NSIT).